Proven Intelligence Accelerating Next-Generation Therapies.

Executive Summary

A comprehensive Chemistry, Manufacturing, and Controls (CMC) package is the foundation for a successful Pre-Investigational New Drug (Pre-IND) meeting with the FDA. For viral vector-based therapies, this requires a detailed assessment of plasmid DNA quality, scalable vector production processes, and phase-appropriate analytical methods. This review identifies potential gaps in the manufacturing process or characterization data that could delay timelines. A proactive CMC strategy minimizes regulatory risk and aligns the development pathway with an 18-24 month timeline to IND submission.

Aligning Manufacturing and Regulatory Expectations

The technical dialogue with the FDA during a Pre-IND meeting hinges on the quality and completeness of the CMC data package. For AAV, lentivirus, or adenovirus platforms, the narrative must demonstrate a controlled, reproducible manufacturing process. A scientific rationale that connects process parameters to the final product’s quality attributes must support the data presentation.

Our approach is built on decades of experience navigating these regulatory interactions. We focus on identifying and mitigating risks within the manufacturing scheme before they become points of contention with regulatory agencies. This provides strategic CMC guidance for regulatory success.

Core Components of a Pre-IND CMC Dossier for Viral Vectors

A robust CMC package for a viral vector therapy is built upon several distinct pillars. Each must be supported by rigorous data to withstand regulatory scrutiny.

• Starting Materials: Comprehensive documentation for all key starting materials, with a primary focus on the quality and provenance of plasmid DNA.

• Vector Production & Purification: A detailed description of the upstream (cell culture, transfection) and downstream (lysis, clarification, chromatography) processes. Data must demonstrate process consistency and clearance of process-related impurities.

• Analytical & Characterization Strategy: A well-defined analytical strategy is needed to assess the vector’s identity, quantity, purity, and potency. This includes methods for genome titer, capsid titer, and aggregation analysis.

• Stability Program: An initial stability protocol and available data are required to support the proposed shelf life and storage conditions for the material intended for IND-enabling toxicology studies.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our collaboration transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is an essential collaborator in our AAV-vector based gene therapy candidate development, and we hope to continue the collaboration for years to come.”
— Biotech Partner

Anticipating and Addressing Immunogenicity Concerns

Pre-existing humoral immunity to AAV vectors presents a known challenge for clinical development. The CMC package must demonstrate an understanding of product-related attributes that could influence immunogenicity. Recent scientific findings, such as those demonstrating the potential for neonatal Fc receptor (FcRn) inhibition to mitigate the impact of neutralizing antibodies (PMID: 36719773), inform our strategic approach. Understanding these biological hurdles allows for a more informed risk assessment of the product’s design and its potential interaction with the patient’s immune system.